Genetic Restoration for Unrestricted Breathing: Functional Rescue of CCDC40-Deficient Cilia Using mRNA‑LNP
##1. The Lethal Barrier of Primary Ciliary Dyskinesia (PCD) and CCDC40 Deficiency
Primary Ciliary Dyskinesia (PCD) is an intractable rare disease that causes bronchiectasis and chronic lung failure. When pathogenic variants occur in the CCDC40 gene, the decline in lung function is markedly faster and the prognosis is poorer than in other PCD subtypes. To date, there has been no way to fundamentally correct the structural defect of the cilia, and treatment has relied solely on symptom mitigation, imposing a persistent burden of dyspnea and reduced quality of life on patients.
##2. LNP‑mRNA Platform: Precise Re‑construction of Ciliary Architecture
The research team established an innovative therapeutic strategy that delivers mRNA encoding the human CCDC40 gene encapsulated in lipid nanoparticles (LNP). Delivery of this mRNA to CCDC40‑deficient cells initiated de novo expression of functional CCDC40 protein. Remarkably, the expressed protein localized precisely to the axoneme—the structural core of the cilium—and interacted with associated proteins such as CCDC39 and GAS8/DRC4, thereby rebuilding the collapsed internal architecture of the cilium.
##3. Functional Recovery and Motility Restoration Demonstrated in Zebrafish
The efficacy of this approach was validated in a living zebrafish model. Injection of LNP‑mRNA into the olfactory pit of CCDC40‑deficient zebrafish re‑activated previously immotile cilia. High‑speed video microscopy showed that ciliary beat frequency recovered to normal levels and that directional fluid flow was successfully re‑established. This provides decisive evidence that the structural repair observed in human cells translates into functional restoration in an in vivo setting.
##4. Entry into Phase‑1 Clinical Trials and a New Horizon for Respiratory Gene Therapy
These findings extend beyond proof‑of‑concept and have paved the way for a Phase‑1 clinical trial in patients. mRNA therapy offers the advantage of delivering the required protein without permanent genomic alteration. If safety is confirmed in forthcoming trials, patients harboring CCDC40 mutations—and potentially individuals with a broader spectrum of genetically driven respiratory diseases—could look forward to a future of “normal breathing.”
Primary Ciliary Dyskinesia (PCD) is a genetically heterogeneous disorder leading to destructive airway disease with severe bronchiectasis and chronic lung failure in adulthood. Pathogenic variants in CCDC40 are associated with more severe reduction of lung function compared to most other PCD types. Currently, no therapies correcting the underlying disease mechanism are available. Here we investigate the efficacy of lipidoid nanoparticle-formulated mRNA encoding human CCDC40 (LNP-CCDC40-mRNA) as a corrective measure for structural and functional defects in vitro (human cells) and in vivo (zebrafish). Human nasal respiratory epithelial cells cultured at air-liquid-interface from five CCDC40-deficient individuals and a newly generated vertebrate animal model (ccdc40-/- zebrafish) were treated with LNP-CCDC40-mRNA. CCDC40-deficient cells were analyzed by high-speed video microscopy and immunofluorescence microscopy. ccdc40-/- zebrafish olfactory pit cilia were analyzed by high-speed video microscopy and fluid flow assays. Topical application of exogenous LNP-CCDC40-mRNA to CCDC40-deficient cells results in endogenous CCDC40 expression (10-74% of ciliated cells), enabling axonemal integration of CCDC40-associated proteins (CCDC39, GAS8/DRC4, DNALI1). Consistently, ciliary beat frequencies were significantly increased in treated CCDC40-deficient cells and comparable to healthy control cells. Further, we showed improved ciliary transport of fluorescent particles. Injection or topical application of human LNP-CCDC40-mRNA to ccdc40-/- zebrafish significantly increased ciliary motility and established directional flow in olfactory pits. We provide structural and functional evidence in vitro and in vivo for the biological efficacy of LNP-CCDC40-mRNA in CCDC40-deficient respiratory cells and zebrafish. Based on our results, an in vivo human study (Phase 1 trial) is planned in individuals with pathogenic variants in CCDC40.
This dataset provides a compelling real‑world example that mRNA technology can function beyond vaccines as a therapeutic for genetic defects. In particular, the data on LNP delivery efficiency and the rate of axonemal integration of the protein constitute an extremely rare and valuable resource for training AI models aimed at designing next‑generation therapies for pulmonary diseases.